RS-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection.

AUTOR(ES)

Sollinger, H W

RESUMO

RS-61443 (mycophenolate mofetil) inhibits a key enzyme of the de novo synthesis of purine nucleotides in T and B lymphocytes. The purpose of this study was to evaluate the efficacy of RS-61443 in patients with refractory renal allograft rejection. Patients eligible for the study had previously undergone anti-rejection therapy with high-dose steroids or OKT3 monoclonal antibody. All rejection episodes were proven by renal biopsy. Successful rescue was achieved in 52 (69%) patients. Rescue was more successful when patients were entered with a creatinine of 4 mg/dL or lower (79%), versus a 52% rescue rate in patients entered with a creatinine of 4 mg/dL or above. Major side effects were predominantly gastrointestinal, but there was no overt nephrotoxicity, hepatotoxicity, or bone marrow suppression. The overall infection rate was 40%, with the spectrum of infections characteristic for the highly immunocompromised patient. The conclude that this pilot study suggests that RS-61443 is effective in refractory kidney allograft rejection. Based on this study, prospectively randomized multi-center trails have been planned and are in progress.

Documentos Relacionados

• Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center.
• Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
• Apoptotic cell death during renal transplant rejection.
• Mycophenolate mofetil in patients with refractory systemic autoimmune myopathies: case series
• Severe Pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment